Opinion|Videos|July 22, 2024
Recent Data on Bimekizumab for Hidradenitis Suppurativa
Author(s)Vivian Shi, MD, FAAD
Vivian Shi, MD, FAAD, reviews recent phase 3 data on bimekizumab, a biologic therapy for patients with hidradenitis suppurativa.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Bimekizumab is a biologic under investigation for hidradenitis suppurativa (HS). What did recent phase 3 results demonstrate?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
